The market’s obsession with data science and artificial intelligence is reflected in this year’s list of 25 companies we think most likely to reach $1 billion valuation.
New study by the St Gallen consortium estimates the cost of one approved drug at $6.16 Billion. 7 of the top 16 pharma companies demonstrated negative R&D productivity.
OpenEvidence, which is valued at $425 million, is taking on one of AI’s big engineering challenges: large language models whose training is stuck in the past.
Amazon is continuing its expansion into the health space with the launch of a new generative AI tool called HealthScribe, meant to take over some time-consuming administrative tasks of doctor’s offices and clinics, the company said.
With a new $59 million investment, digital health startup K Health is looking to scale its AI technology in hospitals, starting with new strategic investor Cedars-Sinai.
In 2023, several breakthroughs have shaken the academic community. Freezing entire organs to sub-zero temperatures for future transplantation is now a reality.
Sanofi made a very important official announcement that went largely unnoticed by the media but has enormous implications for the company and pharmaceutical industry